Risk factors for relapse in patients with Standard Risk B Cell Acute Lymphoblastic Leukemia in a tertiary hospital: A retrospective case control study
- Author:
Ruth Anne A. Tugawin-Montano
1
;
Cindy Faye Alim
1
;
Jerry Pua
1
Author Information
- Publication Type:Journal Article
- Keywords: lymphoblast
- MeSH: leukemia; bone marrow; relapse; recurrence; chemotherapy; drug therapy
- From: The Philippine Children’s Medical Center Journal 2025;21(2):117-129
- CountryPhilippines
- Language:English
-
Abstract:
OBJECTIVES:The overall survival of pediatric acute leukemia improved to >90% in developed countries with chemotherapy but relapse rates still remain at 10% to 20% in developed countries. This study aim to determine the risk factors for relapse in pediatric Standard Risk B Cell ALL. Specifically to describe and compare the socioclinical profile of patients under the relapse and non relapse group.
MATERIALS AND METHODS:Medical records of all children diagnosed with B Cell ALL were reviewed. Demographics and clinical data of patients who relapsed were compared to those who did not. The timing, site and outcome of patients who relapsed were noted. Risk factors for relapse were determined by logistic regression analysis to identify risk prognostic factors of relapse.
RESULTS:A total of 226 patients were included with 58 patients who relapsed and 168 who did not relapse. The mean age of diagnosis in both groups were 4y/o. Majority of the relapsed patients were male 35 (60%) and from outside NCR 35 (60%). Among the risk factors evaluated only the duration of chemotherapy induced agranulocytopenia of > 7 days was identified to be significant risk factor for relapse, p value 0.001.
CONCLUSIONS:The present study determined that > 7 days duration of chemotherapy induced agranulocytopenia is a significant risk for relapse. Future studies with a larger population should be conducted to determine the factors for prolonged chemotherapy induced agranulocytopenia resulting to therapy interruptions that compromises treatment outcome. Cytogenetic and molecular approaches for relapsed ALL would help improve treatment strategies for these patients. - Full text:2026062909492951335Article 7.pdf
